Literature DB >> 23691951

Coagulation and metastasis: what does the experimental literature tell us?

Ana M Gil-Bernabé1, Serena Lucotti, Ruth J Muschel.   

Abstract

Inhibition of coagulation greatly limits cancer metastasis in many experimental models. Cancer cells trigger coagulation, through expression of tissue factor or P-selectin ligands that have correlated with worse prognosis in human clinical studies. Cancer cells also affect coagulation through expression of thrombin and release of microparticles that augment coagulation. In the cancer-bearing host, coagulation facilitates tumour progression through release of platelet granule contents, inhibition of Natural Killer cells and recruitment of macrophages. We are revisiting this literature in the light of recent studies in which treatment of clinical cohorts with anticoagulant drugs led to diminished metastasis.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  aspirin; coagulation; macrophages; metastasis; tissue factor

Mesh:

Substances:

Year:  2013        PMID: 23691951     DOI: 10.1111/bjh.12381

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  36 in total

1.  Impact of chemotherapy on venous thromboembolism: comment to: regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study.

Authors:  Patrizia Ferroni; Silvia Riondino; Fiorella Guadagni; Mario Roselli
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 2.  Crossing the endothelial barrier during metastasis.

Authors:  Nicolas Reymond; Bárbara Borda d'Água; Anne J Ridley
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

3.  Pre-therapeutic fibrinogen levels are of prognostic significance in locally advanced head and neck cancer.

Authors:  Edgar Selzer; Anja Grah; Gregor Heiduschka; Gabriela Kornek; Dietmar Thurnher
Journal:  Wien Klin Wochenschr       Date:  2016-02-26       Impact factor: 1.704

4.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

5.  Selected hemostatic parameters in patients with pancreatic tumors.

Authors:  Anna Deskur; Daria Sałata; Marta Budkowska; Barbara Dołęgowska; Teresa Starzyńska; Wojciech Błogowski
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

6.  Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer.

Authors:  Xiaoguang Yang; Helin Zhang; Fanyi Kong; Guochen Wang; Qianyu Gu; Zheng Zhao; Tiezhi Li; Mingming Ren; Zuosheng Li; Yang Guo
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

7.  Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.

Authors:  Eric T Alexander; Allyson R Minton; Candace S Hayes; Ashley Goss; Joanne Van Ryn; Susan K Gilmour
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 8.  The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells.

Authors:  Amelia Foss; Leonel Muñoz-Sagredo; Jonathan Sleeman; Wilko Thiele
Journal:  Clin Exp Metastasis       Date:  2019-11-22       Impact factor: 5.150

9.  Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Authors:  Devon Pendlebury; Ruiying Wang; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Benjamin J Madden; Marat D Kazanov; Evette S Radisky
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

Review 10.  Small extracellular vesicles in cancer.

Authors:  Komal Abhange; Amy Makler; Yi Wen; Natasha Ramnauth; Wenjun Mao; Waseem Asghar; Yuan Wan
Journal:  Bioact Mater       Date:  2021-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.